⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472866 | 0.72 | — | — | |
| SCHEMBL29022955 | 0.71 | — | — | |
| SCHEMBL9277864 | 0.67 | — | — | |
| SCHEMBL7068253 | 0.67 | — | — | |
| SCHEMBL162813 | 0.67 | — | — | |
| SCHEMBL17548467 | 0.66 | LTA4H (0.56) | — | |
| Hydrochloric Acid SCHEMBL4403057 | 0.65 | — | — | |
| SCHEMBL14248634 | 0.62 | — | — | |
| SCHEMBL2374152 | 0.62 | HSP90AA1 (0.38) | — | |
| SCHEMBL3712929 | 0.62 | CCR4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007002181-A2 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) | ELI LILLY AND COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1648876-A1 | 5-HT SB 2B /SB RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005097113-A2 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| CN-1633291-A | 2-oxazolamines and their use as 5-HT2BUse of receptor antagonists | PHARMAGENE LAB LTD (GB) | 2005-06-29 | — | — | CN | disclosed |
| WO-2005016338-A1 | USE OF 5-HT2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005012263-A1 | 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1474140-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003068226-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |